Dosage and administrationCortexin has an indication-specific dosing, with the most common regime being intramuscular injections once daily. Before injection dissolve content of vial in 1–2 ml of 0.5 % procain (novocain) solution, or water for injection or 0.9 % sodium chloride solution. Adults should use 10 mg per day for the period of 10 days. Cortexin must be taken in the first part of the day, before 3pm. Children weighing less than 20 kg should have 0.5 mg/kg, over 20 kg – 10 mg per day for the period of 10 days. If necessary, the course can be repeated after 3-6 months of discontinuation.
Way of AdministrationPlease use sterile needles, sterilize the administration site, wear sterile plastic gloves, administer as soon as you opened the vial. Please relax your muscle and inject slowly.
Side effectsNo adverse reactions were observed during administration when taken as indicated. Individual hypersensitivity to the product components is possible, so please pay close attention to your body response when you administer the drug for the first time.
Country of Manufacture: RussiaNote: it is much less common, but Cortexin has also been used subcutaneously
US Domestic shipping is available for this product! Choose Ships from: US size option to get it in 3-7 days to any US address. Dont forget to choose US Domestic Shipping when checking out.
Availability: in stock
Cortexin® is a mixture of neuropeptide fractions, amino acids, vitamins and minerals, all of which have a pronounced but subtle positive effect on the brain. Similar to Cerebrolysin, Cortexin is based on neuropeptides and amino acids. However, there is a difference: Cortexin has significantly more peptide fractions and less amino acids.
Cortexin® has the following effects:
Nootropic effect: Improves higher cerebral functions, processes of learning and memory, concentration, attention and tolerance to mental and physical stress;
Neuroprotective effect: protects neurones against different endogenous neurotoxic factors (glutamate, calcium ions and free radicals) and reduces toxic impact of psychotropic agents;
Antioxidant effect: inhibits lipid peroxidation, increases survival of neurones under oxidative stress and hypoxia;
Tissue-specific effect: activates metabolism of neurones of central and peripheral nervous system as well as reparative processes; also, promotes stimulation of cortical function and general improvement of the nervous system.
Mechanism of action of CORTEXIN® is attributed to the following effects:
- Activation of neuronal peptides and neurotrophic cerebral factors;
- Optimisation of metabolic balance of excitatory and inhibitory amino acids as well as dopamine and serotonin;
- GABAergic actions: reduction of the paroxysmal convulsive activity of brain, improvement of its bioelectrical activity and prevention of free radicals formation (products of lipid peroxidation).
Cortexin has the following amino acids, vitamins and minerals:
Amino acids:Aspartic acid: 446 nmol/mg; Glycine: 298 nmol/mg; Threonine: 212 nmol/mg; Serine: 268 nmol/mg; Glutamic acid: 581 nmol/mg; Proline: 187 nmol/mg; Alanine: 246 nmol/mg; Isoleucine: 356 nmol/mg; Tyrosine: 109 nmol/mg; Phenylalanine: 162 nmol/mg; Histidine: 116 nmol/mg; Lysine: 253 nmol/mg; Arginine and other amino acids: 202 nmol/mg.
Vitamins:Lysine: 253 nmol/mg; Thiamine (Vitamin B1) - 0.08 mcg/10mg; Lysine: 253 nmol/mg; Riboflavin (Vitamin B2) - 0.03 mcg/10 mg; Niacin (Vitamin B3, Vitamin PP) 0.05 mcg/10 mg; Retinol (Vitamin A) - 0.011 mcg/10mg; Alfa-tokoferol (vitamin E) - 0.007 mcg/10mg.
Minerals:(Cu): 0,2129 mcg/10 mg; (Fe): 2,26 mcg/10 mg; (Ca): 22,93 mcg/10 mg; (Mg): 8,5 mcg/10 mg; (K): 19,83 mcg/10 mg; (Na): 643,2 mcg/10 mg; (S): 152,65 mcg/10 mg; (P): 91,95 mcg/10 mg; (Zn): 4,73 mcg/10 mg; (Mb): 0,0203 mcg/10 mg; (Co): 0,0044 mcg/10 mg; (Mn): 0,0061 mcg/10 mg; (Se): 0,0745 mcg/10 mg; (Al): 0,3104 mcg/10 mg; (Li): 0,0340 mcg/10 mg.
Country of Manufacture: Russia
Also available in the Children Version (5Mg)
Here is the information about Cortexin from the manufacturer: GEROPHARM
This product has not been approved by the US FDA. All statements on this page are for informational purposes only and have not been evaluated by the US FDA.
This product is not intended to diagnose, treat, cure, or prevent any disease.
- Coulter et al (1993) Identification of cortexin: a novel, neuron-specific, 82-residue membrane protein enriched in rodent cerebral cortex https://www.ncbi.nlm.nih.gov/pubmed/8336151
- Khavinson et al (1999) Cortexin effectiveness in circulatory encephalopathy https://www.ncbi.nlm.nih.gov/pubmed/10356917
- Shabanov et al (2007) Comparison of behavioral effects of cortexin and cerebrolysin injected into brain ventricles https://www.ncbi.nlm.nih.gov/pubmed/18214294
- Shabanov et al (2007) Comparative study of behavioral effects of cortexin and cerebrolysine upon intraventricular and intraperitoneal administration in rats https://www.ncbi.nlm.nih.gov/pubmed/17650626
- Nurguzhaev et al (2009) Use of cortexin in the early rehabilitation period of ischemic stroke of moderate severity https://www.ncbi.nlm.nih.gov/pubmed/19672239
- B Gafurov, Sh Gafurov (2010) Cortexin in the complex treatment of post stroke epilepsy https://www.ncbi.nlm.nih.gov/pubmed/20873481
- A Solov’ev, T Elistratova (2010) Effectiveness of cortexin in the complex treatment of patients with chronic alcohol encephalopathy and polyneuropathy https://www.ncbi.nlm.nih.gov/pubmed/20517210
- Mendzheritsky et al (2015) Pinealon and Cortexin influence on behavior and neurochemical processes in 18-month aged rats within hypoxia and hypothermia https://www.ncbi.nlm.nih.gov/pubmed/28509493
- Belova et al (2016) Efficacy of cortexin in acute and recovery periodes of hemispheric ischemic stroke https://www.ncbi.nlm.nih.gov/pubmed/27845314
- Yakovlev et al (2017) Peptide drug cortexin inhibits brain caspase-8 https://www.ncbi.nlm.nih.gov/pubmed/28251948
- A Yakovlev, N. Gulyaeva (2017) Molecular partners of Cortexin in the brain https://link.springer.com/article/10.1134/S1819712416040164
- Zukov et al (2018) Results of a multicenter study on the efficacy of cortexin in treatment of cognitive dysfunction in children ttps://www.ncbi.nlm.nih.gov/pubmed/29652302h
- N Gulyaeva (2018) Molecular mechanisms of brain peptide-containing drugs: cortexin https://www.ncbi.nlm.nih.gov/pubmed/30499504
- A Fedin (2018) The efficacy of cortexin and memantinol (memantine) in the treatment of cognitive impairment in patients with chronic cerebral ischemia https://www.ncbi.nlm.nih.gov/pubmed/29460902
- Belova et al (2018) Efficacy of Korteksin in acute period of hemispheric ischemic stroke https://www.ncbi.nlm.nih.gov/pubmed/30132453
- Fedin et al (2018) Dose-dependent effects of cortexin in chronic cerebral ischemia (results of a multicenter randomized controlled study) https://www.ncbi.nlm.nih.gov/pubmed/30335070